Fate Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FATE research report →
Range $3.5 – $8
Price Chart
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe.
- CEO
- Bahram Valamehr
- IPO
- 2013
- Employees
- 161
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on FATE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $107.12M
- P/E
- -1.02
- PEG
- -0.04
- P/S
- 25.77
- P/B
- 0.98
- EV/EBITDA
- -1.35
- Div Yield
- 0.00%
- Gross Margin
- 38.57%
- Op Margin
- -2760.04%
- Net Margin
- -2619.64%
- ROE
- -73.92%
- ROIC
- -62.22%
Latest fiscal year · YoY change
- Revenue
- $6.65M-51.2%
- Gross Profit
- $-6,255,000+94.0%
- Op Income
- $-147,704,000
- Net Income
- $-136,315,000+26.8%
- EPS
- $-1.15+29.9%
- OCF Growth
- +13.7%
- FCF Growth
- +9.4%
- 52W High
- $3.23
- 52W Low
- $0.90
- 50D MA
- $2.04
- 200D MA
- $1.98
- Beta
- 2.67
- RSI (14)
- 19
- Avg Volume
- 1.50M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Fate Therapeutics highlighted early autoimmune momentum for FT819 and FT522, backed by ASGCT data and a cash runway into the second half of 2026.· May 9, 2024
- FT819 has moved into autoimmune testing, with the first lupus patient treated and discharged after a 3-day hospital stay with no notable adverse events.
- The company plans to amend the FT819 autoimmune protocol in Q2 2024 to add single-agent cytoxan, aiming to avoid fludarabine in autoimmune settings.
- FT522 data supported the ADR concept: management said the program showed persistence and deep B-cell depletion, and it has started the no-conditioning cohort.
- Fate said it expects multiple clinical readouts in the second half of 2024 across FT819, FT522, and FT825.
- The balance sheet strengthened after a March financing, with cash, cash equivalents and investments of approximately $391 million at quarter end.
Fate reported first-quarter revenue of $1.9 million, flat versus the prior two quarters, tied to research funding under the Ono Pharmaceutical collaboration. R&D expense was $32.1 million, essentially flat sequentially; G&A rose 16% sequentially to $20.9 million; total operating expenses were $53 million, including $11 million of noncash share-based compensation. Net loss was $48 million, or $0.47 per share, and the company recorded a noncash $1.4 million nonoperating loss from the change in fair value of contingent MSK milestone payments. Cash, cash equivalents and investments were approximately $391 million at quarter end after the $80 million underwritten offering and $20 million concurrent private placement; full-year GAAP operating expenses are expected to be $215 million to $230 million, and year-end cash is expected to be more than $270 million.
Scott Wolchko focused on the shift in strategy toward autoimmunity and off-the-shelf cell therapy, arguing that safety, convenience, accessibility, and the ability to add on to standard regimens could make the programs differentiated. He repeatedly emphasized that conditioning chemotherapy is a barrier in autoimmunity and said Fate wants to move toward regimens that look more like standard community treatment rather than oncology-style hospitalization. His tone was confident and program-driven, with several mentions of expected second-half-2024 milestones.
Ed Dulac said the company is in a strong financial position, ending the quarter with about $391 million in cash, cash equivalents and investments after the March financing. He quantified first-quarter spending at $32.1 million in R&D, $20.9 million in G&A, and $53 million in total operating expenses, plus a $1.4 million noncash fair-value loss tied to the MSK contingent milestone liability. He also guided to full-year GAAP operating expenses of $215 million to $230 million and said year-end cash and investments should be more than $270 million, while noting quarterly cash burn has been roughly $37 million to $38 million and could move toward about $40 million as development activity increases.
Analysts pressed management on whether FT819 could work with single-agent cytoxan, and Wolchko said the company believes its bendamustine experience supports an IND amendment adding cytoxan-only conditioning. Questions also focused on FT522 without lymphodepletion; management said the early no-conditioning cohort will help show whether ADR can maintain activity and persistence in an intact immune compartment. Several analysts asked about competition from T-cell engagers and bispecifics, and Wolchko acknowledged the category’s disruptive potential but said Fate is designing its autoimmune programs to compete on safety, add-on use with standard care, and community accessibility as much as on efficacy.
The call offered tangible early autoimmune progress: a first lupus patient dosed with FT819, no notable immediate safety issues, and management’s confidence that the current dose and ex-vivo data support meaningful B-cell depletion. Fate also sees a path for FT522 to work without conditioning chemotherapy, which could differentiate it in both cancer and autoimmune disease. Cash is solid, giving the company time to hit a series of 2024 readouts without near-term financing pressure.
The autoimmune opportunity is still early, with only first-patient or first-few-patient data expected later in 2024, so clinical efficacy remains unproven. Management acknowledged that cy/flu conditioning may be a barrier in autoimmunity and that the field is still figuring out optimal dosing, durability, and whether engagers or other modalities become strong competitors. The company is also winding down or shifting some oncology programs, and spending is still substantial at roughly $37 million to $40 million per quarter in cash burn.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.2%
- Shares Outstanding
- 116.56M
- Float Shares
- 107.49M
of shares held by institutions
163 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for FATE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Redmile Group, LLC | 12.87M | 0 |
| Vanguard Group Inc | 8.97M | ▲ 172.86K |
| Blackrock, Inc. | 7.11M | ▼ 193.72K |
| Vanguard Portfolio Management LLC | 4.96M | ▲ 413.14K |
| Acadian Asset Management LLC | 4.77M | ▲ 414.43K |
| Vanguard Capital Management LLC | 4.50M | ▲ 50.55K |
| Two Sigma Investments, LP | 3.91M | ▲ 315.49K |
| Johnson & Johnson | 3.38M | 0 |
| Renaissance Technologies LLC | 2.37M | ▼ 608.87K |
| Arrowstreet Capital, Limited Partnership | 2.37M | ▲ 2.34M |
| Millennium Management LLC | 2.17M | ▼ 266.43K |
| Goldman Sachs Group Inc | 2.06M | ▲ 12.55K |
Held by 88 ETFs
Biggest fund positions in FATE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Adawi Kamal | sell | 6,582 |
| Aug 4, 26 | TAHL CINDY | sell | 38,800 |
| Aug 4, 26 | Valamehr Bahram | sell | 43,947 |
| Jun 12, 26 | Redmile Group, LLC | other | 87,900 |
| Jun 12, 26 | Lee Michael Stewart | other | 87,900 |
| Jun 12, 26 | Xu Yuan | other | 87,900 |
| Jun 12, 26 | Jooss Karin | other | 87,900 |
| Jun 12, 26 | EPSTEIN ROBERT S | other | 87,900 |
| Jun 12, 26 | Agarwal Shefali | other | 87,900 |
| Jun 12, 26 | ABERNETHY MATT | other | 87,900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FATE coverage
Recent articles, reports, and earnings notes.
Want a deeper read on FATE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Fate Therapeutics Presents New FT819 Data at ACR Convergence 2026 Highlighting Meaningful Clinical Responses in Lupus Without the Use of Conditioning Chemotherapy
globenewswire.com · Nov 10
Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
globenewswire.com · Nov 5
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 3
Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026
globenewswire.com · Oct 26
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 2
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
globenewswire.com · Oct 1
CIRM backs Fate’s FT819 lupus trial
defenseworld.net · Sep 29
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
globenewswire.com · Sep 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
